Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAvalon Hepatitis Testing Coverage | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedAvalon Healthcare SolutionsPolicy AHS-G2036

    Hepatitis Testing

    Customize your policy alerts

    Sign up for avalon_healthcare_solutions Policy AHS-G2036 alerts

    Get alerted when Policy AHS-G2036 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage criteria for laboratory testing used to screen for, diagnose, monitor, and evaluate hepatitis A, B, C, and D infections, subject to the member’s benefit plan and applicable government policies.

    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyHepatitis Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJun 1, 2026
    Last ReviewMar 5, 2026
    Next Review DateN/A
    Key ActionUse the HBV triple panel for initial adult screening and document the relevant risk, pregnancy, immunosuppression, vaccination, or prior testing status.
    SourceLink
    POLICY UPDATE CHANGES

    The policy name was changed from Hepatitis C to Hepatitis Testing and coverage was broadened to include hepatitis B testing.

    Coverage was added for HBV DNA or viral-load testing when the individual has a current or previously diagnosed HBV infection.

    Coverage was added for HCV RNA or viral-load testing when the individual has a current or previously diagnosed HCV infection.

    Coverage was added for HCV antibody testing once every three months for individuals with ongoing risk factors while those risk factors persist.

    Coverage was added for HCV qualitative nucleic-acid testing in immunocompromised individuals.

    Coverage was added for hepatitis A testing in individuals with acute viral hepatitis symptoms who tested negative for HBV and HCV, and for hepatitis D testing in individuals who tested positive for HBV.

    HBV triple-panel screening was added as once-per-lifetime coverage for all individuals aged 18 years and older and for specified high-risk situations.

    Additional CPT and HCPCS codes were added for hepatitis testing, including 86692, 86708, 86709, 87380, 87516, 87523, 87799, and G0567.

    4Hepatitis virus types addressed
    Once per lifetimeAdult HBV triple-panel coverage
    Every 3 monthsOngoing-risk HCV antibody testing
    2–6 monthsPerinatally exposed infant HCV NAT
    12 weeksPost-treatment HCV viral-load confirmation
    2Non-covered quantitative viral-load categories

    Clinical Testing Criteria

    Hepatitis B Testing Criteria

    Covered when the applicable testing indication is met.

    ONE of the following

    • For all individuals age 18 years and older: hepatitis B triple-panel testing—HBsAg, anti-HBs, and total anti-HBc—once per lifetime.
    • For asymptomatic, nonpregnant individuals, annual HBV screening consisting of HBsAg and anti-HBs for infants born to an HBsAg-positive individual.
    • For asymptomatic, nonpregnant individuals, triple-panel testing when ONE high-risk situation applies

      • Born in or recently traveled to a geographic region with HBV prevalence of ≥2%.
      • U.S.-born, not vaccinated as an infant, with parents born in a region with HBV prevalence of ≥8%.
    Policy Summary
    PayerAvalon Healthcare Solutions
    PolicyHepatitis Testing
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJun 1, 2026
    Last ReviewMar 5, 2026
    Next Review DateN/A
    Key ActionUse the HBV triple panel for initial adult screening and document the relevant risk, pregnancy, immunosuppression, vaccination, or prior testing status.
    SourceLink
    On This Page
    Clinical Testing CriteriaCovered Laboratory Codes and Coding ParametersProvider Actions and Coverage ControlsHepatitis Testing BackgroundDefinitions and Laboratory TerminologyCovered Populations, Tests, and Clinical UsesTesting Frequency and Timing LimitsOrdering and Documentation RequirementsNon-Covered Testing
  1. History of incarceration.
  2. HIV infection.
  3. History of sexually transmitted infections or multiple sex partners.
  4. Men who have sex with men.
  5. Household contacts, needle-sharing contacts, or sex partners of an HBV-infected individual.
  6. Current or prior injection-drug use.
  7. Current or prior HCV infection.
  8. Elevated liver enzymes.
  9. Long-term hemodialysis.
  10. Diabetes.
  11. Healthcare or public safety work with blood or body-fluid exposure.
  12. Receipt of immunosuppressant therapy.
  13. For individuals who test positive for anti-HBc: follow-up IgM anti-HBc testing to distinguish acute from chronic infection.
    For confirmation of seroconversion after hepatitis B vaccination: anti-HBs testing.
    For individuals positive by initial HBV antibody screening who will undergo immunosuppressive drug therapy: HBV DNA testing.

    Hepatitis C Testing Criteria

    Covered when the applicable HCV screening, diagnostic, or monitoring indication is met.

    ALL of the following

    • For all individuals age 18 years and older: HCV antibody testing once per lifetime.
    • For any individual with a recognized HCV condition or exposure: one-time post-exposure HCV antibody testing, including current or prior injection or intranasal drug use; pre-1987 clotting-factor concentrates; hemodialysis; liver disease or persistently abnormal ALT; HIV; organ transplant before July 1992; blood transfusion or blood components before July 1992; notification of blood from a donor later positive for HCV; incarceration; tattoo in an unregulated setting; occupational needle-stick, sharps, or mucosal exposure to HCV-positive blood; birth to an HCV-positive individual; or current sexual partnership with an HCV-infected person.
    • For ongoing risk factors while they persist: HCV antibody testing once every three months for current injection-drug use with shared equipment, ongoing hemodialysis, or high-risk sexual behavior.
    • Qualitative HCV nucleic-acid testing for follow-up after a positive initial antibody test, one-time testing of perinatally exposed infants age 2–6 months, or immunocompromised individuals.
    • Before DAA treatment: HCV genotype testing when needed to guide regimen selection.
    • Quantitative HCV RNA testing before DAA therapy, after four weeks of therapy, at treatment completion, and at 12, 24, and 48 weeks after treatment; HCV RNA/viral-load testing is also covered for current or previously diagnosed HCV infection.

    Hepatitis A Testing Criteria

    Covered when acute HAV infection is suspected.

    ALL of the following

    • Signs or symptoms of acute viral hepatitis.
    • Negative HBV and HCV testing.
    • ONE test

      • IgM anti-HAV testing.
      • Qualitative HAV RNA testing.

    Hepatitis D Testing Criteria

    Covered when HBV infection is present.

    ALL of the following

    • Positive HBV testing.
    • ONE test

      • HDV antibody (anti-HDV) testing.
      • Qualitative HDV RNA testing.

    HCV Screening Indications

    CDC recommends HCV screening and confirmation as follows.

    Screening indication

    • All adults age 18 years and older at least once, except where HCV RNA prevalence is less than 0.1%.
    • All pregnant individuals during each pregnancy, except where HCV RNA prevalence is less than 0.1%.
    • One-time testing for recognized conditions or exposures, including injection-drug use, HIV, hemodialysis, persistently abnormal ALT, qualifying transfusion or transplant history, occupational exposure, or birth to an HCV-infected individual.
    • Periodic testing for ongoing risk, including current injection-drug use with shared equipment or maintenance hemodialysis.

    Ongoing HCV Risk and Requested Testing

    Testing should be offered while ongoing risk persists and when requested.

    ANY of the following

    • Current injection-drug use with shared needles, syringes, or drug-preparation equipment.
    • Ongoing hemodialysis.
    • High-risk sexual behavior.
    • The individual requests HCV testing, regardless of stated risk factors.

    HCV Antibody With Reflex RNA Testing

    Use an FDA-approved antibody test followed by nucleic-acid testing when reactive.

    ALL of the following

    • Initiate testing with an HCV antibody test.
    • Automatically perform reflex NAT for HCV RNA when the antibody result is positive or reactive.
    • A reactive antibody indicates past or current infection; detectable HCV RNA indicates current infection.

    Perinatally Exposed Infants

    Covered testing for perinatally exposed infants.

    ALL of the following

    • Infant was perinatally exposed to HCV.
    • Perform HCV RNA NAT at age 2–6 months.

    Occupational HCV Exposure

    Covered post-exposure testing for healthcare personnel.

    ALL of the following

    • Potential occupational exposure to HCV.
    • Testing pathway

      • Test the source patient within 48 hours using HCV RNA or HCV antibody testing.
      • If the source is HCV RNA positive or unavailable, test exposed personnel at baseline, with NAT at 3–6 weeks post-exposure and final HCV antibody testing at 4–6 months.

    HBV Screening Indications

    CDC HBV screening indications include the following.

    Screening population

    • All adults age 18 years and older at least once using a triple panel.
    • Infants born to HBsAg-positive people: HBsAg and anti-HBs testing.
    • Pregnant individuals during each pregnancy: HBsAg, preferably in the first trimester; those with prior triple-panel screening and no subsequent exposure need only HBsAg.
    • Susceptible people with ongoing exposure risk, tested periodically while risk persists.

    HBV Triple-Panel Testing

    The HBV triple panel includes HBsAg, anti-HBs, and total anti-HBc.

    ALL of the following

    • Use the triple panel for initial adult HBV screening.
    • Use the triple panel to identify active infection, resolved infection and reactivation risk, susceptibility, or vaccination.

    HBV Screening Indications — Risk-Based Guidance

    USPSTF and related guidance support screening adolescents and adults at increased risk.

    Increased-risk population

    • Persons born in regions with elevated HBV prevalence, including U.S.-born persons with parents from high-prevalence regions who were not appropriately immunized.
    • Persons who currently or previously injected drugs.
    • Men who have sex with men.
    • Persons with HIV.
    • Sex partners, needle-sharing contacts, or household contacts of persons known to be HBsAg positive.
    • Persons with incarceration history, HCV infection, elevated liver enzymes, diabetes, dialysis, or occupational blood exposure.

    HBV Test Selection and Follow-Up

    Testing selection and follow-up depend on the initial HBV result and clinical setting.

    ALL of the following

    • Use HBsAg and anti-HBs for screening; anti-HBc may be used if persons with positive results receive follow-up HBsAg and anti-HBs testing.
    • After initial triple-panel screening, future periodic testing may use tests appropriate to the clinical situation, such as HBsAg and anti-HBc in an unvaccinated person.
    • Following a positive HBsAg result, use HBV DNA NAT, quantitative or qualitative, to assess viral load, treatment eligibility, and response; reflex HBV DNA testing may be used where available.
    • Individuals with positive screening results should receive medical evaluation, treatment or monitoring as appropriate, and linkage to care.

    AASLD Hepatitis B Screening

    AASLD recommends HBV screening for the following populations.

    Screening population

    • Persons born in countries with HBsAg seroprevalence ≥2%.
    • U.S.-born persons not vaccinated as infants whose parents were born in regions with HBV endemicity ≥8%.
    • Pregnant individuals.
    • Persons needing immunosuppressive therapy.
    • Persons with HIV, HCV, renal dialysis, or other recognized HBV risk factors.

    Acute HAV Testing

    Covered acute HAV testing uses markers appropriate for suspected acute infection.

    ALL of the following

    • Clinical signs or symptoms suggest acute HAV infection.
    • ANY of the following

      • IgM anti-HAV is detected in serum.
      • HAV RNA is detected in serum or stool.

    HAV Test Interpretation

    Interpret HAV serology in the clinical context.

    ANY of the following

    • IgM anti-HAV supports acute HAV infection in a symptomatic patient.
    • IgG anti-HAV indicates immunity from prior infection or vaccination.

    HCV Screening Indications — AASLD-IDSA

    AASLD-IDSA recommends one-time and repeat HCV testing for recognized risk groups.

    Indication

    • One-time routine opt-out testing for all individuals age 18 years and older.
    • One-time testing for persons younger than 18 with HCV risk activities, exposures, conditions, or circumstances.
    • HCV testing during every pregnancy.
    • Periodic repeat testing for ongoing HCV exposure risk.
    • Annual testing for persons who inject drugs, HIV-infected men who have unprotected sex with men, and men who have sex with men taking PrEP.
    • Risk activities or exposures including injection or intranasal drug use, chem sex, long-term hemodialysis, unregulated percutaneous exposure, occupational exposure, perinatal exposure, qualifying transfusion or transplant, incarceration, HIV, PrEP initiation, chronic liver disease, elevated ALT, or organ donation/transplantation.

    Initial HCV Testing and Acute Infection Evaluation

    Use antibody and RNA testing according to exposure timing and clinical circumstances.

    ALL of the following

    • Initial testing: HCV antibody with reflex HCV RNA PCR.
    • Recent exposure within six months with negative antibody: HCV RNA or follow-up antibody testing at least six months after exposure.
    • Immunocompromised person: HCV RNA may be considered despite a negative antibody result.
    • Risk of reinfection after clearance: use initial HCV RNA testing.
    • Suspected acute infection because of exposure, clinical presentation, or elevated aminotransferases: perform HCV antibody and HCV RNA testing.

    HCV Treatment Monitoring

    Covered HCV treatment monitoring includes baseline, on-treatment, and post-treatment assessment.

    ALL of the following

    • Before DAA therapy: quantitative HCV RNA to establish baseline viremia; genotype and subtype if a nonpangenotypic regimen will be used.
    • During or at completion of therapy: quantitative HCV viral load and liver-function assessment as clinically indicated.
    • At least 12 weeks after therapy: quantitative HCV RNA to document sustained virologic response.
    • After treatment failure: disease-progression assessment every 6–12 months with hepatic function panel, CBC, and INR; cirrhosis requires hepatocellular carcinoma surveillance every six months.

    HCV Follow-Up and Special Populations

    Follow-up testing is tailored to treatment response, pregnancy, liver disease, and pediatric status.

    Follow-up circumstance

    • After SVR: confirm undetectable HCV RNA at 12 weeks; consider 24-week testing individually and test at 48 weeks when recommended.
    • Ongoing reinfection risk: periodic HCV RNA testing.
    • Pregnancy: HCV testing each pregnancy; HCV RNA and liver tests at initiation of prenatal care when antibody positive.
    • Children with chronic HCV: routine liver biochemistries at diagnosis and at least annually, with disease-severity assessment using laboratory, examination, elastography, imaging, or fibrosis markers.
    • Perinatally exposed children: antibody testing at or after 18 months; children antibody-positive after 18 months should receive HCV RNA testing after age three.

    HDV Testing

    HDV testing is indicated in persons with HBV, especially HBsAg-positive individuals.

    ALL of the following

    • HBsAg-positive or otherwise confirmed HBV infection.
    • Testing approach

      • Total anti-HDV antibody testing, followed by HDV RNA NAT when anti-HDV positive.
      • Prioritized anti-HDV testing for persons from HDV-endemic regions, advanced liver disease, HBV treatment, low HBV DNA with high ALT, hemodialysis, HCV or HIV, injection-drug use, sex work, or men who have sex with men.
      • Repeat anti-HDV testing when clinically indicated, such as aminotransferase flares or acute decompensation; annual testing may be considered if risk persists.

    WHO Hepatitis C Screening and Confirmation

    WHO recommends person-centered HCV screening and confirmation.

    ALL of the following

    • Offer anti-HCV serologic testing to adults and adolescents in settings with HCV antibody seroprevalence ≥2%, and to identified higher-risk birth cohorts where appropriate.
    • Offer testing to persons with clinical suspicion of chronic viral hepatitis, key populations, people living with HIV, TB, or STIs, people with ongoing risk, and persons with healthcare or non-healthcare invasive exposures.
    • Confirm a positive anti-HCV result with HCV RNA NAT to establish current infection and treatment need.
    • Offer periodic testing, including every 3–6 months for persons with ongoing risk after spontaneous or treatment-induced clearance; consider testing around PrEP initiation and every 12 months in high-risk populations.

    WHO Hepatitis B Screening Populations

    WHO recommends HBV screening in general, specific, and highly affected populations.

    Screening population

    • All adults and adolescents in settings with HBsAg seroprevalence ≥2%.
    • Pregnant individuals as early as possible during pregnancy.
    • Blood donors, healthcare workers not previously vaccinated, and persons with clinical suspicion of chronic viral hepatitis.
    • Key populations: men who have sex with men, sex workers, people who inject drugs, trans and gender-diverse people, and people in prisons or closed settings.
    • PrEP users, sexual partners, children, and household or family contacts of people with HBV infection.
    • Infants born to HBsAg-positive mothers, tested at 6–12 months.
    • Indigenous populations with higher HBV prevalence and adults or adolescents with HIV, TB, STIs, healthcare exposure, or invasive non-healthcare exposure.

    WHO HBV DNA and Reflex Testing

    WHO recommends HBV DNA testing after positive HBsAg testing.

    ALL of the following

    • Positive HBsAg serologic test result.
    • Testing method

      • Laboratory-based quantitative or qualitative HBV DNA NAT to assess viral load, treatment eligibility, and treatment response.
      • Point-of-care HBV DNA NAT when laboratory testing is not used.
      • Reflex HBV DNA testing from the held specimen or immediate follow-up sample where available.

    WHO Hepatitis D Testing

    WHO recommends anti-HDV screening and RNA confirmation in chronic HBV.

    ALL of the following

    • Chronic HBV or HBsAg-positive status.
    • Perform total anti-HDV serology; when positive, perform standardized HDV RNA NAT to identify active viremic infection.
    • Reflex anti-HDV after positive HBsAg and reflex HDV RNA after positive anti-HDV may be used to improve diagnosis and linkage to care.

    IHS Hepatitis Screening and Follow-Up

    IHS recommends HCV screening and confirmatory testing and targeted HBV screening.

    Covered IHS indication

    • HCV screening at least once for adults age 18 years and older, including people with diabetes, regardless of risk factors.
    • HCV screening during each pregnancy, regardless of age.
    • HCV screening for people at higher risk of exposure.
    • After positive HCV antibody screening: laboratory HCV RNA PCR to confirm active infection and refer those with detectable RNA for DAA treatment.
    • After negative HCV antibody with exposure within six months: HCV RNA PCR or follow-up antibody testing at least six months after exposure.
    • People who inject drugs and their substance-use-treatment participants: HBV screening with HBsAg; positive results require counseling, referral, and identification/testing of relevant contacts.

    Covered Hepatitis B Screening

    Covered HBV screening criteria include the following populations and testing approaches.

    ALL of the following

    • Adults age 18 years and older: once-per-lifetime triple-panel testing.
    • Infants born to HBsAg-positive individuals: HBsAg and anti-HBs testing.
    • High-risk individuals: triple-panel testing, including persons from high-prevalence regions, persons with incarceration history, HIV, STI or multiple-partner history, men who have sex with men, contacts of HBV-infected persons, injection-drug use, HCV infection, elevated liver enzymes, hemodialysis, diabetes, occupational blood exposure, or immunosuppressive therapy.

    HBV DNA or Viral-Load Testing

    Covered when HBV infection is current or previously diagnosed.

    ANY of the following

    • Current diagnosis of HBV infection.
    • Previously diagnosed HBV infection.

    Covered Hepatitis A Testing

    Covered HAV testing is limited to acute infection evaluation.

    ANY of the following

    • IgM anti-HAV testing for suspected acute HAV.
    • Qualitative HAV RNA testing for suspected acute HAV.

    Covered Hepatitis D Testing

    Covered HDV testing requires HBV infection or positive HBV testing.

    ANY of the following

    • Anti-HDV antibody testing.
    • Qualitative HDV RNA testing.

    Covered HCV Nucleic-Acid and RNA Testing

    Covered HCV nucleic-acid testing includes diagnostic and viral-load applications.

    ANY of the following

    • Qualitative HCV NAT for follow-up of a positive antibody result, perinatal screening at age 2–6 months, or immunocompromised individuals.
    • Quantitative HCV RNA/viral-load testing before, during, or after DAA treatment.
    • HCV RNA/viral-load testing for current or previously diagnosed HCV infection.

    Periodic HCV Antibody Testing

    Periodic antibody testing is covered while recognized ongoing risk persists.

    ANY of the following

    • Current injection-drug use with shared equipment.
    • Ongoing hemodialysis.
    • High-risk sexual behavior.

    Quantitative nucleic-acid testing for HAV viral load DOES NOT MEET COVERAGE CRITERIA.

    Quantitative nucleic-acid testing for HDV viral load DOES NOT MEET COVERAGE CRITERIA.

    IgG anti-HAV and total anti-HAV are not helpful for diagnosing acute illness. Test IgM anti-HAV only when the patient is symptomatic and HAV infection is suspected.

    HDV antigen is not a reliable marker of current infection, and HDV IgM has less-than-ideal specificity. Total anti-HDV and HDV RNA are the preferred markers for case classification.

    Repetitive HCV RNA testing before 18 months of age is not recommended. Antibody-based testing is recommended at or after 18 months, although a single NAT may be considered as early as two months under current CDC guidance.

    Repeat HCV antibody testing adds cost without clinical benefit. Use HCV RNA testing to assess active versus resolved infection or reinfection.

    Routine HCV RNA testing beyond 48 weeks after the end of treatment to evaluate late relapse is not supported by available evidence. Periodic RNA testing remains appropriate for ongoing reinfection risk.

    EASL states that HCV resistance testing before treatment is not recommended.

    Quantitative nucleic-acid testing for HAV viral load DOES NOT MEET COVERAGE CRITERIA.

    Quantitative nucleic-acid testing for HDV viral load DOES NOT MEET COVERAGE CRITERIA.

    For a patient with a previous positive HCV antibody result, repeat antibody testing provides no clinical benefit; order HCV RNA testing to evaluate active infection.

    AGA recommends HBV screening with HBsAg and anti-HBc, followed by sensitive HBV DNA testing if positive, for patients at moderate or high risk who will undergo immunosuppressive therapy. Routine screening is not recommended for patients at low risk, although screening should follow CDC and USPSTF recommendations when baseline prevalence is likely above 2%.

    Covered Laboratory Codes and Coding Parameters

    Hepatitis serology and antigen CPT codesCPT
    86692Antibody; hepatitis, delta agent.
    86704Hepatitis B core antibody (HBcAb); total.
    86705Hepatitis B core antibody (HBcAb); IgM antibody.
    86706Hepatitis B surface antibody (HBsAb).
    86708Hepatitis B surface antibody (HBsAb) Hepatitis A antibody (HAAb).
    86709Hepatitis A antibody (HAAb), IgM antibody.
    86803Hepatitis C antibody.
    86804Hepatitis C antibody; confirmatory test (eg, immunoblot).
    87340Infectious agent antigen detection by immunoassay technique, including EIA, ELISA, FIA, or IMCA, qualitative or semiquantitative; hepatitis B surface antigen (HBsAg).
    87341Infectious agent antigen detection by immunoassay technique, including EIA, ELISA, FIA, or IMCA, qualitative or semiquantitative; hepatitis B surface antigen (HBsAg) neutralization.
    1–10 of 11
    1/2
    Hepatitis nucleic acid and genotype CPT codesCPT
    87516Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, amplified probe technique.
    87517Infectious agent detection by nucleic acid (DNA or RNA); hepatitis B virus, quantification.
    87520Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, direct probe technique.
    87521Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, amplified probe technique, includes reverse transcription when performed.
    87522Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, quantification, includes reverse transcription when performed.
    87523Infectious agent detection by nucleic acid (DNA or RNA); hepatitis D (delta), quantification, including reverse transcription, when performed.
    87799Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism.
    87902Infectious agent genotype analysis by nucleic acid (DNA or RNA); Hepatitis C virus.
    Hepatitis screening HCPCS codesHCPCS
    G0472Hepatitis C antibody screening, for individual at high risk and other covered indication(s).
    G0472Hepatitis B screening in non-pregnant, high risk individual includes hepatitis B surface antigen (HBsAg), antibodies to HBsAg (anti-HBs) and antibodies to hepatitis B core antigen (anti-HBc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive HBsAg result.
    G0567Infectious agent detection by nucleic acid (DNA or RNA); hepatitis C, screening, amplified probe technique.
    Added hepatitis testing codesmixed
    86704Added CPT code; exact procedure description is not provided in this window.
    86705Added CPT code; exact procedure description is not provided in this window.
    86706Added CPT code; exact procedure description is not provided in this window.
    87340Added CPT code; exact procedure description is not provided in this window.
    87341Added CPT code; exact procedure description is not provided in this window.
    87517Added CPT code; exact procedure description is not provided in this window.
    G0499Added CPT code; exact procedure description is not provided in this window.
    Added hepatitis testing codesCPT
    86692Added CPT code; exact procedure description is not provided in this window.
    86708Added CPT code; exact procedure description is not provided in this window.
    86709Added CPT code; exact procedure description is not provided in this window.
    87380Added CPT code; exact procedure description is not provided in this window.
    87516Added CPT code; exact procedure description is not provided in this window.
    87523Added CPT code; exact procedure description is not provided in this window.
    87799Added CPT code; exact procedure description is not provided in this window.
    Added hepatitis testing codeHCPCS
    G0567Added code; exact procedure description is not provided in this window.
    HBV screening threshold
    Adult threshold18 years of age and older
    TestHBV triple-panel testing
    FrequencyOnce per lifetime
    HBV geographic prevalence thresholds
    Birth or travel regionHBV prevalence of 2% or higher
    U.S.-born individualsParents born in regions with HBV prevalence of 8% or higher, when the individual was not vaccinated as an infant
    ApplicationThese geographic thresholds identify high-risk situations for HBV screening
    Perinatal HCV NAT timing
    PopulationPerinatally exposed infants
    TestQualitative HCV nucleic acid testing
    TimingOne time at 2–6 months of age
    Ongoing-risk HCV antibody frequency
    PopulationIndividuals with ongoing injection-drug use and equipment sharing, ongoing hemodialysis, or high-risk sexual behavior
    TestHCV antibody testing
    FrequencyOnce every three months while risk factors persist
    HCV viral-load monitoring
    TestQuantitative HCV viral-load testing
    During treatmentAfter four weeks of therapy and at the end of treatment
    After treatmentAt 12, 24, and 48 weeks after completion
    Perinatal HCV NAT timing
    PopulationPerinatally exposed infants
    TestHCV NAT
    Timing and frequency2–6 months of age; one time
    HCV antibody testing for ongoing risk
    PopulationIndividuals with ongoing risk factors
    TestHCV antibody testing
    FrequencyOnce every 3 months while risk factors persist
    HBV triple-panel frequency
    PopulationAll individuals 18 years of age and older
    TestHBV triple-panel testing
    FrequencyOnce per lifetime

    Provider Actions and Coverage Controls

    Documentation Required

    Complete HCV testing in one visit

    For complete HCV testing, collect all samples needed to diagnose hepatitis C during a single visit and order HCV RNA testing automatically when the HCV antibody test is reactive.

    Documentation Required

    Use the appropriate HBV screening panel

    Use the HBV triple panel for initial adult screening. Document relevant risk, pregnancy, immunosuppression, vaccination, or prior testing status when selecting the appropriate HBV testing approach.

    • HBsAg
    • Anti-HBs
    • Total anti-HBc
    Documentation Required

    Document the clinical indication

    Document the clinical indication and relevant risk or treatment context supporting testing, including immunosuppressive therapy, pregnancy, HBsAg positivity, HCV antibody positivity, recent exposure, or ongoing reinfection risk.

    Denial Risk

    HAV quantitative viral-load testing is not covered

    Quantitative nucleic acid testing for hepatitis A viral load does not meet coverage criteria.

    Denial Risk

    HDV quantitative viral-load testing is not covered

    Quantitative nucleic acid testing for hepatitis D viral load does not meet coverage criteria.

    Note

    Confirm the controlling coverage policy

    Coverage criteria do not guarantee authorization or payment. The member’s plan contract controls when it conflicts with this policy, and applicable Medicare or Medicaid government policy controls when it conflicts with this policy.

    Denial Risk

    HAV quantitative viral-load testing is not covered

    Quantitative nucleic-acid testing for HAV viral load does not meet coverage criteria.

    Denial Risk

    HDV quantitative viral-load testing is not covered

    Quantitative nucleic-acid testing for HDV viral load does not meet coverage criteria.

    Definitions and Laboratory Terminology

    Definitions
    AbAntibody
    UseSerologic marker used in hepatitis testing
    Related termAg means antigen
    Definitions
    AgAntigen
    UseSubstance detected by antigen testing
    Related termAb means antibody
    Definitions
    HBsAgHepatitis B surface antigen
    RoleSerologic marker used in HBV screening
    Related testingIncluded in the HBV triple panel
    Definitions
    HBVHepatitis B virus
    TestingAssessed with HBsAg, anti-HBs, and total anti-HBc
    Related infectionHDV infection occurs in association with HBV
    Definitions
    HCVHepatitis C virus
    ScreeningInitial screening uses HCV antibody testing
    Active infectionDetected with HCV RNA testing
    Definitions
    HAVHepatitis A virus
    Acute infection testingUses IgM anti-HAV or qualitative HAV RNA
    Clinical contextHAV infection is generally acute and self-limited
    Definitions
    HDVHepatitis D (delta) virus
    AssociationHDV occurs in association with hepatitis B
    TestingUses anti-HDV and HDV RNA testing
    Definitions
    NAATNucleic acid amplification test
    PurposeAmplifies nucleic acid for detection
    Related testingUsed for viral nucleic-acid detection
    Definitions
    NATNucleic acid test
    PurposeDetects viral nucleic acid
    HCV exampleHCV RNA NAT detects current HCV infection
    Definitions
    DAADirect acting anti-viral
    UseAntiviral therapy for HCV infection
    MonitoringHCV viral load is assessed before, during, and after DAA therapy
    Definitions
    IgMImmunoglobulin M
    HAV useIgM anti-HAV indicates acute HAV infection
    HBV useIgM anti-HBc helps distinguish acute from chronic infection
    HCV antibody and RNA interpretation
    Reactive HCV antibodyIndicates past or current HCV infection
    Detectable HCV RNAIndicates current infection
    Follow-upUse NAT for HCV RNA after a positive or reactive antibody result
    Sustained virologic response
    SVRUndetectable HCV RNA 12 weeks after completion of therapy
    PurposeServes as a proxy for elimination of HCV RNA
    Clinical meaningThe treatment goal for HCV infection
    HBV-susceptible person
    Prior infectionThe person has never been infected with HBV
    Vaccination statusThe person did not complete the recommended HepB vaccine series or is a known vaccine nonresponder
    Clinical implicationThe person is susceptible to HBV infection
    Testing strategies
    Two-step strategyInitial antibody detection followed by NAT to confirm active infection
    Viral-first strategyBegins with direct viral RNA detection
    SelectionThe approach depends on test availability and patient population
    HBV triple-panel test
    HBsAgHepatitis B surface antigen
    Anti-HBsAntibody to hepatitis B surface antigen
    Total anti-HBcTotal antibody to hepatitis B core antigen
    Susceptible person
    Prior infectionThe person has never been infected with HBV
    Vaccination statusThe person did not complete an ACIP-recommended HepB vaccine series or is a known vaccine nonresponder
    Clinical implicationThe person is susceptible to HBV infection
    Acute HAV infection
    Serum markerIgM anti-HAV
    Alternative markerHAV RNA in serum or stool
    InterpretationEither marker indicates acute hepatitis A infection
    Probable HDV infection
    ClassificationProbable HDV infection
    Required findingReactive total antibody to hepatitis D virus
    MarkerTotal anti-HDV
    Confirmed HDV infection
    ClassificationConfirmed HDV infection
    Required findingDetection of HDV RNA by nucleic acid testing
    Testing formatsQualitative, quantitative, or genotype testing
    Sustained virologic response
    SVRA post-treatment state consistent with cure of chronic HCV infection
    Laboratory evidenceQuantitative HCV viral-load testing documents the state
    Timing12 or more weeks after completion of therapy
    HCV testing sequence
    Step 1Anti-HCV antibody testing identifies persons previously infected
    Step 2HCV RNA nucleic acid testing confirms current or chronic active infection
    PurposeDistinguishes active infection from resolved infection
    HBV DNA NAT
    TestNucleic acid testing for hepatitis B virus DNA
    FormatQuantitative or qualitative
    PurposeAssess viral load for treatment eligibility and monitor treatment response
    Hepatitis D infection
    AssociationHepatitis D infection is associated with chronic hepatitis B
    First testAnti-HDV antibody testing
    Active infectionHDV RNA testing identifies active viraemic infection
    HBV reactivation
    DefinitionLoss of immunologic suppression of HBV activity
    At-risk markersHBsAg-positive or anti-HBc-positive person
    Typical settingChronic immunosuppression
    Hepatitis B reactivation
    DefinitionLoss of immunologic suppression of hepatitis B virus activity
    At-risk markersPositive hepatitis B surface antigen or hepatitis B core antibody
    Typical settingChronic immunosuppression
    HBVr risk categories
    Low riskLess than 1%
    Moderate risk1–10%
    High riskGreater than 10%
    Sustained virologic response
    SVRUndetectable HCV RNA 12 weeks after completion of an all-oral DAA regimen
    Treatment typeAll-oral direct-acting antiviral treatment
    PurposeConfirms sustained virologic response
    Hepatic function panel
    AlbuminIncluded in the hepatic function panel
    BilirubinTotal and direct bilirubin are included
    EnzymesALT, AST, and alkaline phosphatase are included
    Active HCV infection
    Screening resultPositive HCV antibody test
    ConfirmationLaboratory-based HCV RNA PCR
    InterpretationHCV RNA confirmation indicates active infection

    Covered Populations, Tests, and Clinical Uses

    Covered HBV screening and diagnostic testing indications

    Covered for the following HBV screening and diagnostic indications.

    HBV covered indications: The individual is an adult receiving lifetime triple-panel screening; an asymptomatic non-pregnant person with a listed high-risk situation; anti-HBc-positive receiving IgM anti-HBc; receiving post-vaccination anti-HBs; preparing for immunosuppressive therapy after positive screening; or has current or prior HBV infection requiring HBV DNA or viral-load testing.

    Covered HCV screening, diagnosis, exposure, and monitoring indications

    Covered for screening, diagnosis, exposure, and treatment monitoring.

    HCV covered indications: The individual requires adult screening, recognized-exposure testing, ongoing-risk surveillance, antibody follow-up, perinatal or immunocompromised NAT, genotype testing before DAA therapy, quantitative viral-load testing during treatment or follow-up, or RNA testing for current or prior HCV infection.

    Covered acute HAV evaluation after negative HBV and HCV testing

    Covered when all of the following are met.

    Acute HAV after negative HBV and HCV: The individual has acute viral hepatitis symptoms, negative HBV and HCV testing, and receives IgM anti-HAV or qualitative HAV RNA testing.

    Covered HDV evaluation after positive HBV testing

    Covered when all of the following are met.

    HDV after positive HBV: The individual has tested positive for HBV and receives anti-HDV or qualitative HDV RNA testing.

    HCV screening populations and ongoing-risk testing

    Covered for universal, pregnancy, recognized-risk, or ongoing-risk testing.

    HCV screening and ongoing risk: The individual is an adult aged 18 years or older, pregnant, has a recognized exposure or condition, has ongoing injection-drug use or hemodialysis risk, or requests HCV testing regardless of disclosed risk.At least once; each pregnancy; periodically while risk persists

    HCV NAT indications for infants and recent exposure

    Covered for infants and recent exposure.

    HCV NAT indications: The individual is a perinatally exposed infant aged 2–6 months or has suspected HCV exposure within the prior six months.2–6 months; or recent exposure

    Occupational HCV exposure testing

    Covered after a potential occupational exposure.

    Occupational HCV exposure: Test the source patient within 48 hours and test exposed healthcare personnel at baseline, with NAT at 3–6 weeks and final antibody testing at 4–6 months when the source is RNA-positive or unavailable.

    HBV screening populations and immunosuppression indications

    Covered for screening, pregnancy, exposure risk, and immunosuppression.

    HBV screening populations: The individual is an adult, pregnant, an infant born to an HBsAg-positive person, has ongoing exposure risk, or is receiving or needs immunosuppressive therapy.Adults at least once; pregnancy each pregnancy; periodic while risk persists

    Initial evaluation of chronic HBV infection

    Covered for initial evaluation of chronic HBV infection.

    Chronic HBV evaluation: Evaluate chronic HBV with CBC and platelets, liver chemistries, INR, HBeAg, anti-HBe, HBV DNA, and HAV IgG when clinically appropriate.

    HBV screening populations and triple-panel use

    Use the triple panel for initial adult screening.

    HBV screening and triple-panel use: Screen adults 18 years or older, people requesting testing, pregnant people, infants born to HBsAg-positive people, or people with ongoing HBV exposure risk; use HBsAg, anti-HBs, and total anti-HBc for initial adult screening and HBsAg plus anti-HBs for exposed infants.

    Acute HAV evaluation in symptomatic patients

    Covered when acute HAV is clinically suspected.

    Acute HAV evaluation: The symptomatic individual receives IgM anti-HAV or HAV RNA testing; ALT and total bilirubin may aid diagnosis.

    HCV screening based on age, pregnancy, exposure, and risk

    Covered based on age, pregnancy, exposure, and risk.

    HCV screening: Provide one-time testing to adults 18 years or older; test during each pregnancy; and provide periodic or annual testing for specified injection-drug, sexual, HIV, dialysis, exposure, incarceration, liver disease, transplant, donation, or occupational-risk populations.

    HCV diagnosis, recent exposure, DAA evaluation, and response assessment

    Covered for diagnosis, recent exposure, treatment evaluation, and response assessment.

    HCV diagnostic and treatment indications: Use anti-HCV with reflex RNA for initial diagnosis; RNA for recent exposure, acute infection, or reinfection risk; quantitative RNA before and after treatment; genotype when treatment selection requires it; and RNA at least 12 weeks after treatment to assess response.

    HCV testing during pregnancy and in perinatally exposed children

    Covered for pregnancy and perinatal exposure.

    Pregnancy or pediatric HCV testing: Test during each pregnancy; test exposed children with antibody at or after 18 months, consider RNA earlier, and obtain confirmatory RNA after age three when indicated.

    HDV testing in HBV infection and exposure risk

    Covered for HBV infection or listed HDV exposure risk.

    HDV testing: Test people with HBV or relevant exposure risk using total anti-HDV and HDV RNA as appropriate for case classification.

    HBV screening in high-risk, pregnancy, and immunosuppression populations

    Covered for high-risk, geographic-risk, pregnancy, and immunosuppression populations.

    HBV screening populations: Use HBsAg and anti-HBs in people born in higher-prevalence regions, U.S.-born people with qualifying parental risk, pregnant individuals, or people needing immunosuppression; add anti-HBc for selected HIV, HCV-treatment, anticancer, dialysis, or donated blood/organ settings.

    WHO HCV screening and confirmatory testing indications

    Covered using antibody screening followed by RNA confirmation.

    WHO HCV testing sequence: Perform anti-HCV antibody testing and, when positive, HCV RNA testing to confirm active infection; offer testing to general-population, birth-cohort, clinical-suspicion, exposure-risk, key-population, and comorbidity-based groups.

    WHO HBV screening populations and infant testing

    Covered for any listed HBV screening population.

    WHO HBV screening populations: Offer HBsAg testing in higher-prevalence settings, pregnancy, blood donation, clinical suspicion, unvaccinated healthcare workers, key populations, PrEP users, contacts, exposed infants, higher-prevalence indigenous populations, HIV/TB/STI, or invasive-exposure risk.Infants born to HBsAg-positive mothers: 6–12 months

    HBV DNA NAT after positive HBsAg

    Covered after positive HBsAg.

    HBV DNA NAT: Perform quantitative or qualitative HBV DNA NAT after positive HBsAg to assess viral load, treatment eligibility, and treatment response; laboratory, POC, or reflex testing may be used.

    Anti-HDV and HDV RNA testing indications

    Covered for HBsAg-positive or anti-HDV-positive individuals.

    Anti-HDV and HDV RNA: Perform total anti-HDV testing in HBsAg-positive individuals and HDV RNA NAT in anti-HDV-positive individuals to identify active infection; reflex testing may be used.

    HBV testing before immunosuppressive therapy

    Covered before immunosuppressive therapy when reactivation risk is moderate or high.

    Pre-immunosuppression HBV testing: Use HBsAg and anti-HBc, followed by sensitive HBV DNA testing if positive, in patients at moderate or high HBV reactivation risk who will undergo immunosuppressive therapy.Moderate risk 1–10%; high risk >10%

    HCV SVR confirmation and treatment monitoring

    Covered for SVR confirmation and ongoing treatment monitoring.

    HCV response monitoring: Use HCV RNA at 12 weeks after treatment and routinely at 48 weeks; consider 24-week testing individually and continue periodic RNA testing when reinfection risk persists.

    Chronic HBV evaluation, contact testing, and pregnancy screening

    Covered for chronic HBV evaluation, contacts, and pregnancy.

    HBV evaluation indications: Perform initial chronic HBV evaluation with serologic markers, HBeAg/anti-HBe, HBV DNA, and liver assessment; test first-degree relatives and sexual partners; and screen for HBsAg during the first trimester of pregnancy.

    HDV screening and diagnosis in HBsAg-positive or anti-HDV-positive individuals

    Covered for HBsAg-positive or anti-HDV-positive individuals.

    HDV screening and diagnosis: Perform validated anti-HDV antibody testing at least once in HBsAg-positive individuals and standardized sensitive HDV RNA PCR when anti-HDV is positive or active infection is suspected.

    IHS HCV screening and diagnostic follow-up

    Covered for universal screening, pregnancy, risk, and diagnostic follow-up.

    IHS HCV testing: Screen adults 18 years or older at least once, pregnant persons each pregnancy, and people at increased exposure risk; follow a positive antibody with HCV RNA PCR and recent negative antibody after exposure with RNA or delayed antibody testing.

    Once-per-lifetime HBV triple-panel screening for adults 18 and older

    Covered once per lifetime.

    Adult HBV triple-panel screening: The individual is 18 years of age or older and receives HBsAg, anti-HBs, and total anti-HBc testing.Once per lifetime

    HBV triple-panel screening in specified high-risk situations

    Covered when any specified high-risk situation is present.

    High-risk HBV triple-panel screening: The individual has geographic or travel risk, incarceration, HIV, sexually transmitted infections or multiple partners, sex with men, contact with an HBV-infected person, injection-drug use, current or prior HCV, elevated liver enzymes, long-term hemodialysis, diabetes, or occupational blood/body-fluid exposure.

    HBV DNA or viral-load testing for current or prior HBV infection

    Covered for current or previously diagnosed HBV infection.

    HBV DNA or viral load: The individual has a current diagnosis of HBV infection or a previously diagnosed HBV infection.

    Acute HAV testing after negative HBV and HCV testing

    Covered after negative HBV and HCV testing.

    Acute HAV testing: The individual has acute viral hepatitis symptoms, negative HBV and HCV testing, and receives IgM anti-HAV or qualitative HAV RNA testing.

    Anti-HDV or qualitative HDV RNA after positive HBV testing

    Covered after positive HBV testing.

    HDV testing: The individual has a positive HBV test and receives anti-HDV or qualitative HDV RNA testing.

    Qualitative HCV nucleic-acid testing in specified situations

    Covered in any specified situation.

    Qualitative HCV NAT: The individual has a positive HCV antibody screen, is a perinatally exposed infant aged 2–6 months, is immunocompromised, or has current or previously diagnosed HCV infection.

    Testing Frequency and Timing Limits

    Adult HBV triple-panel frequency
    PopulationIndividuals 18 years of age and older
    TestHBV triple-panel testing
    FrequencyOnce per lifetime
    Annual HBV screening
    PopulationAsymptomatic, non-pregnant individuals
    TestAnnual HBV screening
    Qualifying situationsInfant born to an HBsAg-positive individual or a listed high-risk situation
    Adult HCV antibody frequency
    PopulationIndividuals 18 years of age and older
    TestHCV antibody testing
    FrequencyOnce per lifetime
    Ongoing-risk HCV antibody frequency
    Qualifying risksInjection-drug use with equipment sharing, ongoing hemodialysis, or high-risk sexual behavior
    TestHCV antibody testing
    FrequencyOnce every three months while risk factors persist
    Post-exposure HCV antibody frequency
    PopulationIndividuals with recognized HCV exposures or conditions
    TestHCV antibody testing
    FrequencyOne time after exposure
    Perinatal HCV NAT frequency
    PopulationPerinatally exposed infants aged 2–6 months
    TestQualitative HCV nucleic acid testing
    FrequencyOne time
    Quantitative HCV viral-load time points
    Before therapyBefore initiation of DAA therapy
    During therapyAfter four weeks of therapy and at the end of treatment
    After therapy12, 24, and 48 weeks after completion
    General adult HCV screening
    PopulationAll adults aged 18 years and older
    TestHCV screening
    FrequencyAt least once
    HCV screening during pregnancy
    PopulationAll pregnant individuals
    TestHCV screening
    FrequencyDuring each pregnancy
    Adult HBV triple-panel screening
    PopulationAll adults aged 18 years and older
    TestHBV triple-panel screening
    FrequencyAt least once
    Periodic viral hepatitis testing
    TestsHCV or HBV testing
    FrequencyPeriodic testing
    DurationWhile ongoing risk or exposure persists
    Perinatal HCV RNA timing
    PopulationPerinatally exposed infants
    TestHCV RNA NAT
    TimingAt 2–6 months of age
    Healthcare personnel exposure schedule
    Source testingBaseline testing within 48 hours after exposure
    Exposed-person NAT3–6 weeks post-exposure
    Final testingHCV antibody at 4–6 months post-exposure
    Adult HBV lifetime frequency
    PopulationAdults
    TestHBV triple-panel screening
    FrequencyAt least once in a lifetime
    HBsAg screening during pregnancy
    PopulationPregnant people
    TestHBsAg screening
    FrequencyEach pregnancy, preferably in the first trimester
    HCV screening during pregnancy
    PopulationAll pregnant individuals
    TestHCV screening
    FrequencyEach pregnancy
    Annual HCV testing for higher-risk groups
    People who inject drugsAnnual HCV testing
    HIV-infected men with unprotected sex with menAnnual HCV testing
    Men who have sex with men taking PrEPAnnual HCV testing
    Post-treatment HCV viral-load timing
    TestQuantitative HCV viral load
    Timing12 or more weeks after completion of therapy
    PurposeDocument sustained virologic response
    Post-treatment laboratory follow-up
    TestsHepatic function panel, CBC, and INR
    FrequencyEvery six to twelve months
    PopulationPatients not retreated or who fail a second or third DAA course
    Hepatocellular carcinoma surveillance
    TestLiver ultrasound with or without AFP
    PurposeHepatocellular carcinoma surveillance
    FrequencyEvery six months for patients with cirrhosis
    Routine liver biochemistry frequency
    TestRoutine liver biochemistries
    PopulationChildren with chronic HCV
    FrequencyAt least annually after initial diagnosis
    HCV antibody testing for PrEP populations
    PopulationHigh-risk populations receiving PrEP services
    Initial testingAt or within 1–3 months of PrEP initiation
    Repeat testingEvery 12 months thereafter
    HCV viraemia monitoring
    PopulationPeople with ongoing HCV risk and prior treatment-induced or spontaneous clearance
    TestHCV viraemia, generally HCV RNA
    FrequencyEvery 3–6 months
    Infant HBsAg testing
    PopulationInfants born to mothers with HBsAg
    TestHBsAg
    TimingBetween 6 and 12 months of age
    HBsAg testing for PrEP users
    PopulationPrEP users, particularly in highly endemic countries
    TestHBsAg
    Timing and frequencyOnce at or within 1–3 months of PrEP initiation
    HCV RNA SVR confirmation
    SVR confirmationUndetectable HCV RNA at 12 weeks after completion of all-oral DAA therapy
    Routine confirmationHCV RNA at 48 weeks post-treatment
    Ongoing riskPeriodic HCV RNA testing when reinfection risk persists
    HCV RNA beyond 48 weeks
    Beyond 48 weeksDo not routinely test solely to evaluate late virologic relapse
    Ongoing reinfection riskPeriodic HCV RNA testing is recommended
    Individual considerationTesting at 24 weeks post-treatment may be considered
    Anti-HDV testing frequency
    PopulationAll HBsAg-positive individuals
    TestAnti-HDV antibody
    FrequencyAt least once; repeat when clinically indicated and consider annually if risk remains
    Adult and pregnancy HCV screening
    AdultsHCV antibody screening at least once for adults 18 years and older
    PregnancyHCV antibody screening during each pregnancy
    Additional populationPeople at higher risk of HCV exposure
    HCV follow-up after recent exposure
    Initial resultNegative HCV antibody after possible exposure within the previous six months
    Follow-up option 1HCV RNA PCR
    Follow-up option 2Repeat HCV antibody testing at least six months after exposure
    Adult HBV triple-panel lifetime frequency
    PopulationIndividuals 18 years of age and older
    TestHBV triple-panel testing
    FrequencyOnce per lifetime
    Perinatal HCV NAT frequency
    PopulationPerinatally exposed infants
    TestQualitative HCV nucleic-acid testing
    FrequencyOne time at age 2–6 months
    Ongoing-risk HCV antibody frequency
    PopulationIndividuals with ongoing risk factors
    TestHCV antibody testing
    FrequencyOnce every 3 months while risk factors persist

    Ordering and Documentation Requirements

    Billing Rule

    Order FDA-approved HCV antibody testing with reflex NAT

    Order an FDA-approved HCV antibody test followed by NAT for HCV RNA when the antibody result is positive or reactive. Laboratories should automatically perform reflex NAT after a reactive antibody result.

    • Use HCV RNA NAT to detect current infection after a reactive antibody result.
    • For suspected exposure within the previous 6 months, perform HCV RNA testing regardless of the antibody result.
    Note

    Honor requested HCV testing

    Test anyone who requests an HCV test regardless of stated risk factors.

    Note

    Honor requested HBV testing

    Anyone who requests HBV testing should receive it regardless of disclosure of risk.

    Note

    Coordinate care for infants with detectable HCV RNA

    Coordinate care for infants with detectable HCV RNA with a provider who has expertise in pediatric hepatitis C management.

    • Test every perinatally exposed infant for HCV RNA using NAT at 2 to 6 months.
    • Infants with undetectable HCV RNA do not require further follow-up unless clinically warranted.
    Note

    Order HBV screening and follow-up as clinically indicated

    HBV screening and follow-up may be ordered by clinicians. Following an HBV diagnosis, medical evaluation may be provided by a primary care clinician or a chronic liver disease specialist.

    Billing Rule

    Confirm initially reactive HBsAg results

    Use an FDA-approved HBsAg assay and obtain confirmatory testing for initially reactive HBsAg results.

    Billing Rule

    Use reflex HCV RNA PCR for initial evaluation

    Use HCV-antibody testing with reflex HCV RNA PCR for initial HCV evaluation when feasible.

    Note

    Order genotype testing when treatment selection requires it

    Obtain HCV genotype and subtype before treatment when a nonpangenotypic direct-acting antiviral will be prescribed.

    Note

    Specialist ordering is not required

    Testing and treatment may be delivered in primary care, harm-reduction sites, prisons, and by trained non-specialist doctors and nurses; specialist ordering is not required by the cited recommendations.

    Note

    Select the HCV testing approach appropriate to the setting

    HCV testing may be offered through facility-based, community-based, self-testing, laboratory-based RNA, or point-of-care RNA approaches depending on the setting and population.

    Note

    No restricted ordering provider type specified

    The document does not specify a restricted provider type for ordering these tests.

    Documentation Required

    Match the order to the clinical context

    Order testing according to the patient’s clinical indication, exposure risk, pregnancy status, treatment status, or HBV or HDV serologic findings.

    Non-Covered Testing

    The following services do not meet coverage criteria or are not recommended for routine use: quantitative HAV viral-load testing; quantitative HDV viral-load testing; IgG anti-HAV or total anti-HAV used alone to diagnose acute HAV illness; HDV antigen testing and HDV IgM for current-infection classification; repetitive HCV RNA testing before 18 months of age; routine repeat HCV antibody testing after a prior positive result; routine HBV screening before immunosuppressive therapy in low-risk patients; routine HCV resistance testing before treatment; and routine HCV RNA testing beyond 48 weeks after treatment solely to evaluate late virologic relapse.